• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Phase III trial shows survival benefit for early multiple myeloma

byTomi Jun
February 14, 2014
in Chronic Disease, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: CC/Osaro

1. Treatment with lenalidomide and dexamethasone significantly delayed disease progression in patients with smoldering multiple myeloma who were at high risk for progression.

2. Treatment with lenalidomide and dexamethasone improved survival in such patients.

3. The treatment was associated with more adverse events than observation (current standard).

Evidence Rating Level: 1 (Excellent) 

Study Rundown: Smoldering multiple myeloma (SMM) is a premalignant stage of multiple myeloma. Patients with SMM have a 10% annual risk of disease progression. Such patients are closely followed but not treated because studies thus far have failed to show that early treatment reduces mortality.

RELATED REPORTS

Talquetamab and teclistamab combination improved response in relapsed multiple myeloma

#VisualAbstract: Daratumumab Reduces Risk of Progression in High-Risk Smoldering Multiple Myeloma

Sanofi’s Sarclisa approved as first-line for transplant-ineligible multiple myeloma patients

In this study, the authors tested the efficacy of oral lenalidomide and dexamethasone therapy among SMM patients with a high risk for progression. Since there is no consensus on how to identify high-risk SMM, the authors used their own interpretation of current criteria.

The authors found that the lenalidomide and dexamethasone therapy not only significantly delayed disease progression, but also produced a survival benefit. At three years, 77% of the patients who received lenalidomide had progression-free survival, compared with 30% in the observation group. However, this benefit must be balanced against the risk of adverse effects, which included serious infections, rashes, constipation and diarrhea.

This small study is notable as it has succeeded in showing a survival benefit from early treatment of SMM where other trials have failed. This success may be related to the purposeful selection of high-risk SMM patients, which had not been done before. Further studies should address the impact of this regimen on quality of life, which was not assessed.

Click to read the study, published today in NEJM

Relevant Reading: Early versus deferred treatment for early stage multiple myeloma

In-Depth [randomized controlled trial]: 119 patients with high-risk SMM in Spain and Portugal were randomized to either observation or treatment. Treatment included an induction phase consisting of nine four-week cycles of lenalidomide and dexamethasone followed by maintenance therapy with lenalidomide until progression or until two years from the start of treatment. Dexamethasone was added to the maintenance regimen if asymptomatic progression occurred.

The primary end point was time to progression to symptomatic myeloma. Secondary end points were response rate, overall survival, and safety. Median time to progression was 21 months in the observation group. Less than 50% of the patients in the treatment group had disease progression by the end of the trial, so the median was not reached. The hazard ratio for progression was 0.18 (95% CI, 0.09 to 0.32, P<0.001). Median overall survival was not reached in either group. At 3 years, 94% of patients in the treatment group remained alive versus 80% in the observation group, resulting in a hazard ratio for death of 0.31 (95% CI, 0.10 to 0.91; P=0.03).

The incidence of infection did not differ between the treatment and observation group, but the rate of serious adverse events due to infection was higher in the treatment group.

More from this author: Early risk factor for progression of cystic fibrosis identified, Gut microbes implicated in stroke and heart attacks: new dietary link, New leukemia mutation offers therapeutic targets, Childhood ADHD associated with increased risk of suicide, A marker of aggressive liver cancer and potential therapeutic target identified

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.  

Tags: dexamethasonehealthlenalidomidemultiple myelomasmolderingSmoldering multiple myeloma
Previous Post

The TRANSFORMS trial: Fingolimod vs interferon in multiple sclerosis [Classics Series]

Next Post

MERS remains poorly understood, deadly

RelatedReports

The STORM trial: treatment refractory multiple myeloma patients experience response with selinexor
Chronic Disease

Talquetamab and teclistamab combination improved response in relapsed multiple myeloma

March 6, 2025
#VisualAbstract: Daratumumab Reduces Risk of Progression in High-Risk Smoldering Multiple Myeloma
StudyGraphics

#VisualAbstract: Daratumumab Reduces Risk of Progression in High-Risk Smoldering Multiple Myeloma

December 26, 2024
Phase III trial shows survival benefit for early multiple myeloma
Pharma

Sanofi’s Sarclisa approved as first-line for transplant-ineligible multiple myeloma patients

October 22, 2024
Niraparib may lengthen progression-free survival for patients with recurrent ovarian cancer
Chronic Disease

Brentuximab-based chemotherapy improves survival and reduces toxicity in patients with advanced Hodgkin lymphoma

August 28, 2024
Next Post
Emerging coronavirus found to spread in healthcare facilities

MERS remains poorly understood, deadly

Rituximab noninferior to conventional therapy in ANCA-associated vasculitis: RAVE Trial

Rituximab noninferior to conventional therapy in ANCA-associated vasculitis: RAVE Trial

Soaring rates of peripheral artery disease, now over 200 million cases worldwide

Soaring rates of peripheral artery disease, now over 200 million cases worldwide

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • St. Louis hospital-based violence intervention program did not significantly affect reinjury outcomes
  • Glucagon-like peptide-1 receptor agonists may increase risk of reflux in patients with type 2 diabetes
  • Vaporized nicotine products may be effective for smoking cessation among people with social disadvantage
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.